Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the KSA.
Campus
Campus

EAS guidance regarding combining Lipid-modifying therapy

Watch the video and learn on how to integrate recommendations by European Atherosclerosis Society (EAS) Task Force on combining lipid-modifying therapy into routine practice and have positive impact on Atherosclerotic Cardiovascular Disease (ASCVD) trajectory and burden in high- and very-high-risk patients.

Related articles
Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients

Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients

Read article
Lp(a) as ASCVD risk factor

Lp(a) as ASCVD risk factor

Read article
Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

Read article
MAT-BH-2200016/v2/Jun 2023